Simon Lord
University of Oxford(GB)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Glioma Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Cancer, Hypoxia, and Metabolism, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Fatty Acid Uptake and Lipid Storage Induced by HIF-1α Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation(2014)654 cited
- → Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study(2019)550 cited
- → Imaging tumour hypoxia with positron emission tomography(2014)324 cited
- → Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications(2022)202 cited
- → Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer(2021)183 cited
- → Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer(2019)127 cited
- → Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer(2018)125 cited
- → Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?(2023)124 cited
- → The current status of risk-stratified breast screening(2021)123 cited
- → BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).(2021)106 cited